Artisan Partners flags Insmed as key detractor in Q2 global equity report
The Artisan Global Opportunities Strategy posted a 12.65 per cent net return, lagging the MSCI ACWI Index as Insmed’s BRINSUPRI sales fell short of elevated expectations.
Artisan Partners has released its second-quarter 2026 investor commentary for the Artisan Global Opportunities Strategy, reporting a net return of 12.65 per cent. The fund underperformed the MSCI ACWI Index, which returned 15.3 per cent during the period, a result attributed to the portfolio’s underweight exposure to information technology and its overweight position in health care.
Global equities rebounded sharply in the quarter, supported by resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence. These factors helped lift markets despite persistent inflation, higher bond yields, and geopolitical uncertainty. Strong stock selection in technology and energy partially offset the sectoral headwinds faced by the fund.
The commentary identified Insmed Incorporated as a primary portfolio detractor, alongside BAE Systems and L3Harris Technologies. Insmed, a biotechnology company focused on pulmonary diseases, saw sales for its new therapy, BRINSUPRI, come in modestly below elevated investor expectations. The shortfall reflected concerns regarding discontinuation rates, continuation on therapy, and typical early-year seasonality.
Despite the short-term disappointment, Artisan management stated that the underlying launch trajectory remains encouraging. The fund’s due diligence suggests the therapy is well tolerated and on track to achieve blockbuster-level sales. Consequently, management trimmed its position in Insmed during the quarter but continues to view it as a significant long-term opportunity.
Insmed’s financial performance has been driven largely by the new drug, with total revenues increasing by 296 per cent to $425.5 million. This growth was primarily fuelled by a $309.2 million contribution from BRINSUPRI. As of 1 September 2026, Insmed shares closed at $121.51, giving the company a market capitalisation of $27.14 billion.
Investor interest in the stock has also shifted, with the number of hedge fund portfolios holding Insmed rising from 67 in the previous quarter to 88 at the end of the second quarter. The fund’s management noted that while Insmed offers potential, certain AI stocks currently provide greater upside potential with less downside risk.
